Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. FDA Launches First Overseas Office in Beijing

This article was originally published in PharmAsia News

Executive Summary

U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress

You may also be interested in...



Biden’s Visit Highlights China-U.S. Cooperation On API Oversight And Patent Protection

Last week, U.S. Vice President Joe Biden visited China, Japan, and South Korean during a six-day Asia trip. One of Biden’s goals in China was to strengthen collaboration between the two countries on food and drug safety as well as patent protection.

China 2014 Regulatory Outlook: Expect Greater Enforcement As CFDA Rolls Out New Regs

The year 2014 could see China FDA implement a series of rules, including revisions to the Drug Registration Regulation and the Medical Device Administration Regulation, which could significantly impact the pharmaceutical and medical device industries.

China 2014 Regulatory Outlook: Expect Greater Enforcement As CFDA Rolls Out New Regs

The year 2014 could see China FDA implement a series of rules, including revisions to the Drug Registration Regulation and the Medical Device Administration Regulation, which could significantly impact the pharmaceutical and medical device industries.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel